9989 — Shenzhen Hepalink Pharmaceutical Co Share News
0.000.00%
Last trade - 00:00- HK$5.93bn
- HK$5.70bn
- CNY5.48bn
Brief: Shenzhen Hepalink Pharmaceutical Says Sun Xuan Resigned As Vice Chairman And Executive Director
Brief: Shenzhen Hepalink Pharmaceutical Group Posts QTRLY Net Profit Attributable Of RMB143.5 Million
Brief: Shenzhen Hepalink Pharmaceutical Says "Heptris" Obtained Approval From Brazilian Health Regulatory Agency
Brief: Shenzhen Hepalink Pharmaceutical Group Proposes To Appoint Zhang Bin As An Executive Director
Brief: Shenzhen Hepalink Pharmaceutical Says Inhixa Obtains Approval In North Macedonia
Brief: Shenzhen Hepalink Pharmaceutical Group Posts FY Non-IFRS Profit Attributable RMB592 Million
Brief: Shenzhen Hepalink Pharmaceutical Says Unit Entered Into Share Transfer Agreement With, Among Others, Sanofi Foreign Participations BV
Brief: Shenzhen Hepalink Pharma's To Sell Asset In Kymab
Brief: Shenzhen Hepalink Pharmaceutical Says Enoxaparin Sodium Injection Obtains Approval From Health Canada
Brief: Shenzhen Hepalink Pharmaceutical Group Says Co's H Shares Will Be Newly Included In FTSE Global Equity Index Series
Brief: Shenzhen Hepalink Pharmaceutical Qtrly Net Profit Attributable RMB127.5 Mln
Brief: Shenzhen Hepalink Pharmaceutical Says Unit Got Approval Notice Of Supplementary Drug Application
Brief: Shenzhen Hepalink Pharma To Boost Unit's Capital For Investing In Healthcare Fund
Brief: Shenzhen Hepalink Pharmaceutical Says Unit's "Enoxaparin Sodium Injection" Obtains U.S. FDA Approval
Shenzhen Hepalink Pharma, MBV Int'l drop on Hong Kong debuts
Brief: Shenzhen Hepalink Says OncoQuest Inc Plans To Sell Assets To South Korea's Dual Industrial
Brief: Aridis Pharmaceuticals And Hepalink Entered Amendment To JV Agreement
Brief: Resverlogix reports $87 mln private placement with Shenzhen Hepalink
Brief: Shenzhen Hepalink Pharmaceutical to invest in Canada's Resverlogix Corp